JNJ Johnson & Johnson
Execution beat my October story, but at $279 the market prices a margin JNJ rarely sustains.
The story
J&J is now a pure innovative medicine and MedTech company after the Kenvue split, and its scale, diversification and oncology/immunology franchise (Darzalex, Carvykti, Tremfya, Rybrevant) give it a wide moat. It has absorbed Stelara biosimilar erosion faster than feared and grown revenue to about $99B, roughly 5.5% a year, helped by the Shockwave and Intra-Cellular deals. It is a mature but still-reinvesting franchise. The TTM 18.8% GAAP margin is depressed by acquisition charges, IPR&D and talc-related items, and last year's 35.6% was inflated by the Kenvue gain; neither one is the sustainable level.
Growth goes up slightly from 6% to 6.5% and margin from 29% to 31% because the new launches have now proven they can more than offset the Stelara cliff. Horizon moves from 8 to 10 years (a 25% change) because the pipeline's depth and the deals now absorbed point to a longer excess-return runway than I assumed in October. Sales-to-capital stays at 1.2 rather than the 0.77 TTM figure, since acquired goodwill depresses the TTM number and organic reinvestment is more efficient; beta and failure risk are unchanged, with talc litigation as the tail risk.
Value drivers
| Revenue growth (Y1) | 6.5% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 31.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.1% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 159.45B |
| PV of terminal value | 204.98B |
| Equity value | 329.48B |
| ÷ shares → per share | $136.87 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 105.79B | 6.5% | 21.3% | 18.52B | 5.38B | 13.14B | 12.04B |
| 2 | 112.26B | 6.1% | 23.7% | 21.89B | 5.39B | 16.51B | 13.86B |
| 3 | 118.68B | 5.7% | 26.1% | 25.52B | 5.35B | 20.17B | 15.52B |
| 4 | 125.01B | 5.3% | 28.6% | 29.38B | 5.27B | 24.11B | 17.01B |
| 5 | 131.19B | 4.9% | 31.0% | 33.46B | 5.15B | 28.31B | 18.30B |
| 6 | 137.17B | 4.6% | 31.0% | 34.98B | 4.98B | 30.00B | 17.78B |
| 7 | 142.88B | 4.2% | 31.0% | 36.44B | 4.76B | 31.68B | 17.20B |
| 8 | 148.28B | 3.8% | 31.0% | 37.82B | 4.50B | 33.32B | 16.58B |
| 9 | 153.31B | 3.4% | 31.0% | 39.10B | 4.19B | 34.91B | 15.92B |
| 10 | 157.90B | 3.0% | 31.0% | 40.27B | 3.83B | 36.44B | 15.23B |
Key risks
- IRA Medicare price negotiation and MFN drug-pricing pressure compressing pharma margins
- Talc litigation outcome after the bankruptcy-route rejection
- Biosimilar erosion (Stelara, later Darzalex) outpacing new-launch ramp
Catalysts
- Tremfya, Rybrevant and Caplyta label expansions driving above-consensus Innovative Medicine growth
- MedTech margin recovery from electrophysiology/Shockwave scale and possible portfolio pruning (e.g., orthopaedics separation)